Global High Content Screening

High Content Screening Comprehensive Study by Type (Instruments (Cell Imaging and Analysis Systems, Flow Cytometers), Consumables (Reagents and Assay Kits, Micro plates, other), Software, Services, Accessories), Application (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling, Others), End Users (Pharmaceutical and Biotechnology Companies, Academic and Government Institutions, Contract Research Organization) Players and Region - Global Market Outlook to 2026

High Content Screening Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
High content screening includes analysis of whole cells or components. It is used in biological research or developments and identifies the elements such as peptides, small molecules, or genetic materials. It consists of image capturing software, evaluation and data storage. Moreover, it employs a set of procedures like multi parameter, image processing, automated microscopy, fluorescence image and others. Hence these factors are increasing the demand for high content screening.This growth is primarily driven by Rising Investments in Research and Developments and Increasing Usage of High Throughput Screening for Drug Development.

Globally, a noticeable market trend is evident Development of New Drugs for Various Diseases.. Major Players, such as Molecular Devices (United States), Thermo Fisher Scientific (United States), PerkinElmer Inc. (United States), Becton (United States), GE Healthcare (United States), Dickinson and Company (United States), Merck KGaA (Germany), Cell Signaling Technology (United States), Thorlabs, Inc. (United States) and Genedata AG (Switzerland) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
In May 2019, Thermo Fisher Scientific has acquired Brammer Bio which is a manufacturer of vector for gene and cell therapy.

Market Drivers
  • Rising Investments in Research and Developments
  • Increasing Usage of High Throughput Screening for Drug Development

Market Trend
  • Development of New Drugs for Various Diseases.

Restraints
  • Rising Costs of Content Screening Instruments
  • Stringent Regulations in Various Countries

Opportunities
Technological Advancements in Imaging Solutions and Growing Prevalence of Genetic Disorders and Neurological Diseases
Challenges
Lack of Skilled Professionals

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, High Content Screening Study Sheds Light on
— The High Content Screening Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the High Content Screening industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where High Content Screening industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Instruments (Cell Imaging and Analysis Systems, Flow Cytometers)
  • Consumables (Reagents and Assay Kits, Micro plates, other)
  • Software
  • Services
  • Accessories
By Application
  • Primary and Secondary Screening
  • Target Identification and Validation
  • Toxicity Studies
  • Compound Profiling
  • Others
By End Users
  • Pharmaceutical and Biotechnology Companies
  • Academic and Government Institutions
  • Contract Research Organization

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Investments in Research and Developments
      • 3.2.2. Increasing Usage of High Throughput Screening for Drug Development
    • 3.3. Market Challenges
      • 3.3.1. Lack of Skilled Professionals
    • 3.4. Market Trends
      • 3.4.1. Development of New Drugs for Various Diseases.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global High Content Screening, by Type, Application, End Users and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global High Content Screening (Value)
      • 5.2.1. Global High Content Screening by: Type (Value)
        • 5.2.1.1. Instruments (Cell Imaging and Analysis Systems, Flow Cytometers)
        • 5.2.1.2. Consumables (Reagents and Assay Kits, Micro plates, other)
        • 5.2.1.3. Software
        • 5.2.1.4. Services
        • 5.2.1.5. Accessories
      • 5.2.2. Global High Content Screening by: Application (Value)
        • 5.2.2.1. Primary and Secondary Screening
        • 5.2.2.2. Target Identification and Validation
        • 5.2.2.3. Toxicity Studies
        • 5.2.2.4. Compound Profiling
        • 5.2.2.5. Others
      • 5.2.3. Global High Content Screening by: End Users (Value)
        • 5.2.3.1. Pharmaceutical and Biotechnology Companies
        • 5.2.3.2. Academic and Government Institutions
        • 5.2.3.3. Contract Research Organization
      • 5.2.4. Global High Content Screening Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. High Content Screening: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Molecular Devices (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Thermo Fisher Scientific (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. PerkinElmer Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Becton (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GE Healthcare (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Dickinson and Company (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Merck KGaA (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Cell Signaling Technology (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Thorlabs, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Genedata AG (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global High Content Screening Sale, by Type, Application, End Users and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global High Content Screening (Value)
      • 7.2.1. Global High Content Screening by: Type (Value)
        • 7.2.1.1. Instruments (Cell Imaging and Analysis Systems, Flow Cytometers)
        • 7.2.1.2. Consumables (Reagents and Assay Kits, Micro plates, other)
        • 7.2.1.3. Software
        • 7.2.1.4. Services
        • 7.2.1.5. Accessories
      • 7.2.2. Global High Content Screening by: Application (Value)
        • 7.2.2.1. Primary and Secondary Screening
        • 7.2.2.2. Target Identification and Validation
        • 7.2.2.3. Toxicity Studies
        • 7.2.2.4. Compound Profiling
        • 7.2.2.5. Others
      • 7.2.3. Global High Content Screening by: End Users (Value)
        • 7.2.3.1. Pharmaceutical and Biotechnology Companies
        • 7.2.3.2. Academic and Government Institutions
        • 7.2.3.3. Contract Research Organization
      • 7.2.4. Global High Content Screening Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. High Content Screening: by Type(USD Million)
  • Table 2. High Content Screening Instruments (Cell Imaging and Analysis Systems, Flow Cytometers) , by Region USD Million (2015-2020)
  • Table 3. High Content Screening Consumables (Reagents and Assay Kits, Micro plates, other) , by Region USD Million (2015-2020)
  • Table 4. High Content Screening Software , by Region USD Million (2015-2020)
  • Table 5. High Content Screening Services , by Region USD Million (2015-2020)
  • Table 6. High Content Screening Accessories , by Region USD Million (2015-2020)
  • Table 7. High Content Screening: by Application(USD Million)
  • Table 8. High Content Screening Primary and Secondary Screening , by Region USD Million (2015-2020)
  • Table 9. High Content Screening Target Identification and Validation , by Region USD Million (2015-2020)
  • Table 10. High Content Screening Toxicity Studies , by Region USD Million (2015-2020)
  • Table 11. High Content Screening Compound Profiling , by Region USD Million (2015-2020)
  • Table 12. High Content Screening Others , by Region USD Million (2015-2020)
  • Table 13. High Content Screening: by End Users(USD Million)
  • Table 14. High Content Screening Pharmaceutical and Biotechnology Companies , by Region USD Million (2015-2020)
  • Table 15. High Content Screening Academic and Government Institutions , by Region USD Million (2015-2020)
  • Table 16. High Content Screening Contract Research Organization , by Region USD Million (2015-2020)
  • Table 17. South America High Content Screening, by Country USD Million (2015-2020)
  • Table 18. South America High Content Screening, by Type USD Million (2015-2020)
  • Table 19. South America High Content Screening, by Application USD Million (2015-2020)
  • Table 20. South America High Content Screening, by End Users USD Million (2015-2020)
  • Table 21. Brazil High Content Screening, by Type USD Million (2015-2020)
  • Table 22. Brazil High Content Screening, by Application USD Million (2015-2020)
  • Table 23. Brazil High Content Screening, by End Users USD Million (2015-2020)
  • Table 24. Argentina High Content Screening, by Type USD Million (2015-2020)
  • Table 25. Argentina High Content Screening, by Application USD Million (2015-2020)
  • Table 26. Argentina High Content Screening, by End Users USD Million (2015-2020)
  • Table 27. Rest of South America High Content Screening, by Type USD Million (2015-2020)
  • Table 28. Rest of South America High Content Screening, by Application USD Million (2015-2020)
  • Table 29. Rest of South America High Content Screening, by End Users USD Million (2015-2020)
  • Table 30. Asia Pacific High Content Screening, by Country USD Million (2015-2020)
  • Table 31. Asia Pacific High Content Screening, by Type USD Million (2015-2020)
  • Table 32. Asia Pacific High Content Screening, by Application USD Million (2015-2020)
  • Table 33. Asia Pacific High Content Screening, by End Users USD Million (2015-2020)
  • Table 34. China High Content Screening, by Type USD Million (2015-2020)
  • Table 35. China High Content Screening, by Application USD Million (2015-2020)
  • Table 36. China High Content Screening, by End Users USD Million (2015-2020)
  • Table 37. Japan High Content Screening, by Type USD Million (2015-2020)
  • Table 38. Japan High Content Screening, by Application USD Million (2015-2020)
  • Table 39. Japan High Content Screening, by End Users USD Million (2015-2020)
  • Table 40. India High Content Screening, by Type USD Million (2015-2020)
  • Table 41. India High Content Screening, by Application USD Million (2015-2020)
  • Table 42. India High Content Screening, by End Users USD Million (2015-2020)
  • Table 43. South Korea High Content Screening, by Type USD Million (2015-2020)
  • Table 44. South Korea High Content Screening, by Application USD Million (2015-2020)
  • Table 45. South Korea High Content Screening, by End Users USD Million (2015-2020)
  • Table 46. Taiwan High Content Screening, by Type USD Million (2015-2020)
  • Table 47. Taiwan High Content Screening, by Application USD Million (2015-2020)
  • Table 48. Taiwan High Content Screening, by End Users USD Million (2015-2020)
  • Table 49. Australia High Content Screening, by Type USD Million (2015-2020)
  • Table 50. Australia High Content Screening, by Application USD Million (2015-2020)
  • Table 51. Australia High Content Screening, by End Users USD Million (2015-2020)
  • Table 52. Rest of Asia-Pacific High Content Screening, by Type USD Million (2015-2020)
  • Table 53. Rest of Asia-Pacific High Content Screening, by Application USD Million (2015-2020)
  • Table 54. Rest of Asia-Pacific High Content Screening, by End Users USD Million (2015-2020)
  • Table 55. Europe High Content Screening, by Country USD Million (2015-2020)
  • Table 56. Europe High Content Screening, by Type USD Million (2015-2020)
  • Table 57. Europe High Content Screening, by Application USD Million (2015-2020)
  • Table 58. Europe High Content Screening, by End Users USD Million (2015-2020)
  • Table 59. Germany High Content Screening, by Type USD Million (2015-2020)
  • Table 60. Germany High Content Screening, by Application USD Million (2015-2020)
  • Table 61. Germany High Content Screening, by End Users USD Million (2015-2020)
  • Table 62. France High Content Screening, by Type USD Million (2015-2020)
  • Table 63. France High Content Screening, by Application USD Million (2015-2020)
  • Table 64. France High Content Screening, by End Users USD Million (2015-2020)
  • Table 65. Italy High Content Screening, by Type USD Million (2015-2020)
  • Table 66. Italy High Content Screening, by Application USD Million (2015-2020)
  • Table 67. Italy High Content Screening, by End Users USD Million (2015-2020)
  • Table 68. United Kingdom High Content Screening, by Type USD Million (2015-2020)
  • Table 69. United Kingdom High Content Screening, by Application USD Million (2015-2020)
  • Table 70. United Kingdom High Content Screening, by End Users USD Million (2015-2020)
  • Table 71. Netherlands High Content Screening, by Type USD Million (2015-2020)
  • Table 72. Netherlands High Content Screening, by Application USD Million (2015-2020)
  • Table 73. Netherlands High Content Screening, by End Users USD Million (2015-2020)
  • Table 74. Rest of Europe High Content Screening, by Type USD Million (2015-2020)
  • Table 75. Rest of Europe High Content Screening, by Application USD Million (2015-2020)
  • Table 76. Rest of Europe High Content Screening, by End Users USD Million (2015-2020)
  • Table 77. MEA High Content Screening, by Country USD Million (2015-2020)
  • Table 78. MEA High Content Screening, by Type USD Million (2015-2020)
  • Table 79. MEA High Content Screening, by Application USD Million (2015-2020)
  • Table 80. MEA High Content Screening, by End Users USD Million (2015-2020)
  • Table 81. Middle East High Content Screening, by Type USD Million (2015-2020)
  • Table 82. Middle East High Content Screening, by Application USD Million (2015-2020)
  • Table 83. Middle East High Content Screening, by End Users USD Million (2015-2020)
  • Table 84. Africa High Content Screening, by Type USD Million (2015-2020)
  • Table 85. Africa High Content Screening, by Application USD Million (2015-2020)
  • Table 86. Africa High Content Screening, by End Users USD Million (2015-2020)
  • Table 87. North America High Content Screening, by Country USD Million (2015-2020)
  • Table 88. North America High Content Screening, by Type USD Million (2015-2020)
  • Table 89. North America High Content Screening, by Application USD Million (2015-2020)
  • Table 90. North America High Content Screening, by End Users USD Million (2015-2020)
  • Table 91. United States High Content Screening, by Type USD Million (2015-2020)
  • Table 92. United States High Content Screening, by Application USD Million (2015-2020)
  • Table 93. United States High Content Screening, by End Users USD Million (2015-2020)
  • Table 94. Canada High Content Screening, by Type USD Million (2015-2020)
  • Table 95. Canada High Content Screening, by Application USD Million (2015-2020)
  • Table 96. Canada High Content Screening, by End Users USD Million (2015-2020)
  • Table 97. Mexico High Content Screening, by Type USD Million (2015-2020)
  • Table 98. Mexico High Content Screening, by Application USD Million (2015-2020)
  • Table 99. Mexico High Content Screening, by End Users USD Million (2015-2020)
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. High Content Screening: by Type(USD Million)
  • Table 111. High Content Screening Instruments (Cell Imaging and Analysis Systems, Flow Cytometers) , by Region USD Million (2021-2026)
  • Table 112. High Content Screening Consumables (Reagents and Assay Kits, Micro plates, other) , by Region USD Million (2021-2026)
  • Table 113. High Content Screening Software , by Region USD Million (2021-2026)
  • Table 114. High Content Screening Services , by Region USD Million (2021-2026)
  • Table 115. High Content Screening Accessories , by Region USD Million (2021-2026)
  • Table 116. High Content Screening: by Application(USD Million)
  • Table 117. High Content Screening Primary and Secondary Screening , by Region USD Million (2021-2026)
  • Table 118. High Content Screening Target Identification and Validation , by Region USD Million (2021-2026)
  • Table 119. High Content Screening Toxicity Studies , by Region USD Million (2021-2026)
  • Table 120. High Content Screening Compound Profiling , by Region USD Million (2021-2026)
  • Table 121. High Content Screening Others , by Region USD Million (2021-2026)
  • Table 122. High Content Screening: by End Users(USD Million)
  • Table 123. High Content Screening Pharmaceutical and Biotechnology Companies , by Region USD Million (2021-2026)
  • Table 124. High Content Screening Academic and Government Institutions , by Region USD Million (2021-2026)
  • Table 125. High Content Screening Contract Research Organization , by Region USD Million (2021-2026)
  • Table 126. South America High Content Screening, by Country USD Million (2021-2026)
  • Table 127. South America High Content Screening, by Type USD Million (2021-2026)
  • Table 128. South America High Content Screening, by Application USD Million (2021-2026)
  • Table 129. South America High Content Screening, by End Users USD Million (2021-2026)
  • Table 130. Brazil High Content Screening, by Type USD Million (2021-2026)
  • Table 131. Brazil High Content Screening, by Application USD Million (2021-2026)
  • Table 132. Brazil High Content Screening, by End Users USD Million (2021-2026)
  • Table 133. Argentina High Content Screening, by Type USD Million (2021-2026)
  • Table 134. Argentina High Content Screening, by Application USD Million (2021-2026)
  • Table 135. Argentina High Content Screening, by End Users USD Million (2021-2026)
  • Table 136. Rest of South America High Content Screening, by Type USD Million (2021-2026)
  • Table 137. Rest of South America High Content Screening, by Application USD Million (2021-2026)
  • Table 138. Rest of South America High Content Screening, by End Users USD Million (2021-2026)
  • Table 139. Asia Pacific High Content Screening, by Country USD Million (2021-2026)
  • Table 140. Asia Pacific High Content Screening, by Type USD Million (2021-2026)
  • Table 141. Asia Pacific High Content Screening, by Application USD Million (2021-2026)
  • Table 142. Asia Pacific High Content Screening, by End Users USD Million (2021-2026)
  • Table 143. China High Content Screening, by Type USD Million (2021-2026)
  • Table 144. China High Content Screening, by Application USD Million (2021-2026)
  • Table 145. China High Content Screening, by End Users USD Million (2021-2026)
  • Table 146. Japan High Content Screening, by Type USD Million (2021-2026)
  • Table 147. Japan High Content Screening, by Application USD Million (2021-2026)
  • Table 148. Japan High Content Screening, by End Users USD Million (2021-2026)
  • Table 149. India High Content Screening, by Type USD Million (2021-2026)
  • Table 150. India High Content Screening, by Application USD Million (2021-2026)
  • Table 151. India High Content Screening, by End Users USD Million (2021-2026)
  • Table 152. South Korea High Content Screening, by Type USD Million (2021-2026)
  • Table 153. South Korea High Content Screening, by Application USD Million (2021-2026)
  • Table 154. South Korea High Content Screening, by End Users USD Million (2021-2026)
  • Table 155. Taiwan High Content Screening, by Type USD Million (2021-2026)
  • Table 156. Taiwan High Content Screening, by Application USD Million (2021-2026)
  • Table 157. Taiwan High Content Screening, by End Users USD Million (2021-2026)
  • Table 158. Australia High Content Screening, by Type USD Million (2021-2026)
  • Table 159. Australia High Content Screening, by Application USD Million (2021-2026)
  • Table 160. Australia High Content Screening, by End Users USD Million (2021-2026)
  • Table 161. Rest of Asia-Pacific High Content Screening, by Type USD Million (2021-2026)
  • Table 162. Rest of Asia-Pacific High Content Screening, by Application USD Million (2021-2026)
  • Table 163. Rest of Asia-Pacific High Content Screening, by End Users USD Million (2021-2026)
  • Table 164. Europe High Content Screening, by Country USD Million (2021-2026)
  • Table 165. Europe High Content Screening, by Type USD Million (2021-2026)
  • Table 166. Europe High Content Screening, by Application USD Million (2021-2026)
  • Table 167. Europe High Content Screening, by End Users USD Million (2021-2026)
  • Table 168. Germany High Content Screening, by Type USD Million (2021-2026)
  • Table 169. Germany High Content Screening, by Application USD Million (2021-2026)
  • Table 170. Germany High Content Screening, by End Users USD Million (2021-2026)
  • Table 171. France High Content Screening, by Type USD Million (2021-2026)
  • Table 172. France High Content Screening, by Application USD Million (2021-2026)
  • Table 173. France High Content Screening, by End Users USD Million (2021-2026)
  • Table 174. Italy High Content Screening, by Type USD Million (2021-2026)
  • Table 175. Italy High Content Screening, by Application USD Million (2021-2026)
  • Table 176. Italy High Content Screening, by End Users USD Million (2021-2026)
  • Table 177. United Kingdom High Content Screening, by Type USD Million (2021-2026)
  • Table 178. United Kingdom High Content Screening, by Application USD Million (2021-2026)
  • Table 179. United Kingdom High Content Screening, by End Users USD Million (2021-2026)
  • Table 180. Netherlands High Content Screening, by Type USD Million (2021-2026)
  • Table 181. Netherlands High Content Screening, by Application USD Million (2021-2026)
  • Table 182. Netherlands High Content Screening, by End Users USD Million (2021-2026)
  • Table 183. Rest of Europe High Content Screening, by Type USD Million (2021-2026)
  • Table 184. Rest of Europe High Content Screening, by Application USD Million (2021-2026)
  • Table 185. Rest of Europe High Content Screening, by End Users USD Million (2021-2026)
  • Table 186. MEA High Content Screening, by Country USD Million (2021-2026)
  • Table 187. MEA High Content Screening, by Type USD Million (2021-2026)
  • Table 188. MEA High Content Screening, by Application USD Million (2021-2026)
  • Table 189. MEA High Content Screening, by End Users USD Million (2021-2026)
  • Table 190. Middle East High Content Screening, by Type USD Million (2021-2026)
  • Table 191. Middle East High Content Screening, by Application USD Million (2021-2026)
  • Table 192. Middle East High Content Screening, by End Users USD Million (2021-2026)
  • Table 193. Africa High Content Screening, by Type USD Million (2021-2026)
  • Table 194. Africa High Content Screening, by Application USD Million (2021-2026)
  • Table 195. Africa High Content Screening, by End Users USD Million (2021-2026)
  • Table 196. North America High Content Screening, by Country USD Million (2021-2026)
  • Table 197. North America High Content Screening, by Type USD Million (2021-2026)
  • Table 198. North America High Content Screening, by Application USD Million (2021-2026)
  • Table 199. North America High Content Screening, by End Users USD Million (2021-2026)
  • Table 200. United States High Content Screening, by Type USD Million (2021-2026)
  • Table 201. United States High Content Screening, by Application USD Million (2021-2026)
  • Table 202. United States High Content Screening, by End Users USD Million (2021-2026)
  • Table 203. Canada High Content Screening, by Type USD Million (2021-2026)
  • Table 204. Canada High Content Screening, by Application USD Million (2021-2026)
  • Table 205. Canada High Content Screening, by End Users USD Million (2021-2026)
  • Table 206. Mexico High Content Screening, by Type USD Million (2021-2026)
  • Table 207. Mexico High Content Screening, by Application USD Million (2021-2026)
  • Table 208. Mexico High Content Screening, by End Users USD Million (2021-2026)
  • Table 209. Research Programs/Design for This Report
  • Table 210. Key Data Information from Secondary Sources
  • Table 211. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global High Content Screening: by Type USD Million (2015-2020)
  • Figure 5. Global High Content Screening: by Application USD Million (2015-2020)
  • Figure 6. Global High Content Screening: by End Users USD Million (2015-2020)
  • Figure 7. South America High Content Screening Share (%), by Country
  • Figure 8. Asia Pacific High Content Screening Share (%), by Country
  • Figure 9. Europe High Content Screening Share (%), by Country
  • Figure 10. MEA High Content Screening Share (%), by Country
  • Figure 11. North America High Content Screening Share (%), by Country
  • Figure 12. Global High Content Screening share by Players 2020 (%)
  • Figure 13. Global High Content Screening share by Players (Top 3) 2020(%)
  • Figure 14. Global High Content Screening share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Molecular Devices (United States) Revenue, Net Income and Gross profit
  • Figure 17. Molecular Devices (United States) Revenue: by Geography 2020
  • Figure 18. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 19. Thermo Fisher Scientific (United States) Revenue: by Geography 2020
  • Figure 20. PerkinElmer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. PerkinElmer Inc. (United States) Revenue: by Geography 2020
  • Figure 22. Becton (United States) Revenue, Net Income and Gross profit
  • Figure 23. Becton (United States) Revenue: by Geography 2020
  • Figure 24. GE Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 25. GE Healthcare (United States) Revenue: by Geography 2020
  • Figure 26. Dickinson and Company (United States) Revenue, Net Income and Gross profit
  • Figure 27. Dickinson and Company (United States) Revenue: by Geography 2020
  • Figure 28. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 29. Merck KGaA (Germany) Revenue: by Geography 2020
  • Figure 30. Cell Signaling Technology (United States) Revenue, Net Income and Gross profit
  • Figure 31. Cell Signaling Technology (United States) Revenue: by Geography 2020
  • Figure 32. Thorlabs, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Thorlabs, Inc. (United States) Revenue: by Geography 2020
  • Figure 34. Genedata AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 35. Genedata AG (Switzerland) Revenue: by Geography 2020
  • Figure 36. Global High Content Screening: by Type USD Million (2021-2026)
  • Figure 37. Global High Content Screening: by Application USD Million (2021-2026)
  • Figure 38. Global High Content Screening: by End Users USD Million (2021-2026)
  • Figure 39. South America High Content Screening Share (%), by Country
  • Figure 40. Asia Pacific High Content Screening Share (%), by Country
  • Figure 41. Europe High Content Screening Share (%), by Country
  • Figure 42. MEA High Content Screening Share (%), by Country
  • Figure 43. North America High Content Screening Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Molecular Devices (United States)
  • Thermo Fisher Scientific (United States)
  • PerkinElmer Inc. (United States)
  • Becton (United States)
  • GE Healthcare (United States)
  • Dickinson and Company (United States)
  • Merck KGaA (Germany)
  • Cell Signaling Technology (United States)
  • Thorlabs, Inc. (United States)
  • Genedata AG (Switzerland)
Additional players considered in the study are as follows:
Yokogawa Electric Corporation (Japan)
Select User Access Type

Key Highlights of Report


May 2021 203 Pages 70 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global High Content Screening Quantitative research analysis
Global High Content Screening Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global High Content Screening Report?

Have a Query? Click Here

Other Related Reports

Microbiology Testing Comprehensive Study by Type (Instruments, Reagents), Application (Pharmaceutical, Clinical, Food Testing, Energy, Chemical and Material Manufacturing, Environment), Disease Area ...
$ 3650
Gene Gun Comprehensive Study by Type (Desktop Type, Handhold Type, Other), Application (Agriculture, Medical, Others) Players and Region - Global Market Outlook to 2030
$ 3500
Biologic Drugs Comprehensive Study by Type (Vaccines, Blood and Blood Components, Allergenics, Somatic Cells, Gene Therapy, Tissues, Recombinant Therapeutic Proteins), Application (Cancer, Rheumatoid...
$ 3650
Cephalosporin Comprehensive Study by Type (Branded, Generics), Application (Respiratory Tract Infection, Skin Infection, Ear Infection, Urinary Tract Infection, Sexually Transmitted Infection, Others...
$ 3750
Xylanase Comprehensive Study by Type (Feed grade, Food grade), Application (Feed and livestock, Bleaching of wood pulp, Additive (in poultry), Bakery, Agro waste treatment), End User Industry (Paper ...
$ 3450
Oligonucleotide Pool Library Comprehensive Study by Type (12K Different Oligo per Pools, 90K Different Oligo per Pools, Other), Application (Target Capture, CRISPR/Cas9 Designs, Gene Synthesis, Libra...
$ 3350